Yamamoto N - Search Results

1

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N. Murakami H, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10. Cancer Chemother Pharmacol. 2012. PMID: 22071596 Clinical Trial.

2

A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.

Hotta K, Sekine I, Tamura T, Sawada M, Watanabe H, Kusaba H, Akiyama Y, Inoue A, Shimoyama T, Nokihara H, Ueda Y, Yamamoto N, Kunitoh H, Ohe Y, Kodama T, Saijo N. Hotta K, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2001 Dec;31(12):596-600. doi: 10.1093/jjco/hye129. Jpn J Clin Oncol. 2001. PMID: 11902490 Clinical Trial.

3

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials.

Tanai C, Nokihara H, Yamamoto S, Kunitoh H, Yamamoto N, Sekine I, Ohe Y, Tamura T. Tanai C, et al. Among authors: yamamoto n, yamamoto s. Br J Cancer. 2009 Apr 7;100(7):1037-42. doi: 10.1038/sj.bjc.6604982. Epub 2009 Mar 17. Br J Cancer. 2009. PMID: 19293799 Free PMC article.

4

Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai T, Nishio M. Ohyanagi F, et al. Among authors: yamamoto n. Br J Cancer. 2009 Jul 21;101(2):225-31. doi: 10.1038/sj.bjc.6605152. Br J Cancer. 2009. PMID: 19603031 Free PMC article. Clinical Trial.

5

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.

Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T. Tanioka M, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2011 Aug;68(2):505-11. doi: 10.1007/s00280-010-1506-7. Epub 2010 Nov 16. Cancer Chemother Pharmacol. 2011. PMID: 21079959 Clinical Trial.

6

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.

Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T. Nishio M, et al. Among authors: yamamoto n. Br J Cancer. 2013 Aug 6;109(3):538-44. doi: 10.1038/bjc.2013.374. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860537 Free PMC article. Clinical Trial.

7

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.

Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa K. Yamamoto N, et al. Br J Cancer. 2013 Nov 26;109(11):2803-9. doi: 10.1038/bjc.2013.588. Epub 2013 Oct 29. Br J Cancer. 2013. PMID: 24169346 Free PMC article. Clinical Trial.

8

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.

Murakami H, Kurata T, Onozawa Y, Watanabe J, Ono A, Takahashi T, Yamamoto N, Fujisaka Y, Kiyota H, Hayashi H, Tanaka K, Nakagawa K, Kuroda S. Murakami H, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2014 Mar;73(3):623-30. doi: 10.1007/s00280-014-2388-x. Epub 2014 Jan 30. Cancer Chemother Pharmacol. 2014. PMID: 24477603 Free PMC article. Clinical Trial.

9

Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.

Naito T, Seto T, Takeda K, Goto K, Okamoto I, Nakagawa K, Ohba T, Murakami H, Takahashi T, Yamanaka T, Yamamoto N. Naito T, et al. Among authors: yamamoto n. Lung Cancer. 2014 Dec;86(3):339-43. doi: 10.1016/j.lungcan.2014.10.010. Epub 2014 Oct 23. Lung Cancer. 2014. PMID: 25453619 Clinical Trial.

10

New strategies for cancer therapy in the 21st century.

Saito N, Tamura T, Yamamoto N, Nishio K. Saito N, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S102-6. doi: 10.1007/s002800100315. Cancer Chemother Pharmacol. 2001. PMID: 11587358 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,216 results

Search Page